期刊文献+

WuTac血药浓度双抗体夹心定量ELISA检测方法的建立及其临床应用 被引量:2

Development and Clinical Application of Double Antibody Sandwich ELISA for WuTac Concentration in Serum
原文传递
导出
摘要 目的建立WuTac血药浓度双抗体夹心定量ELISA检测方法,并进行初步临床应用。方法建立双抗体夹心ELISA法,定量检测血清中WuTac浓度,筛选最佳抗体包被浓度和酶标抗体稀释度,绘制标准曲线,并对该方法进行验证;应用该方法对36名健康志愿者单次注射不同剂量WuTac(0.05、0.1和0.2mg/kg)前后14个时间点的临床血清标本进行检测。结果最佳抗体包被浓度为0.2μg/ml,最佳酶标抗体稀释度为1∶15000,标准曲线的线性相关系数r≥0.99,线性范围为3.9~125ng/ml。高浓度WuTac标准品的变异系数小于15%;准确性为99.05%±5.00%(92.43%~110.02%);特异性良好。临床血清检测结果表明,WuTac在0.05~0.2mg/kg范围内呈线性药代动力学特征。结论已建立了WuTac血药浓度双抗体夹心定量ELISA检测方法,该方法的灵敏度、精密性和准确性均符合我国生物制品药代动力学研究的要求。 Objective To develop a double antibody sandwich ELISA for WuTac concentration in serum and preliminarily apply in clinic. Methods The WuTac concentration in sera was determined quantitatively by double antibody sandwich ELISA, based on which the concentration of coating antibody and the dilution of enzyme-labeled antibody were optimized and a standard curve was plotted. The developed ELISA was verified and used for the determination of serum specimens from 36 healthy volunteers at 14 time points before and after injection with WuTac at various dosages (0. 05, 0. 1 and 0. 2 mg/kg). Results The optimal concentration of coating antibody was 0. 2 p,g/ml, and the optimal dilution of enzyme-labeled antibody was 1 : 15 000. The correlation coefficient (r value) of standard curve was not less than 0. 99. The linear determination range of developed double antibody sandwich ELISA was 3.9 - 125 ng/ml. The variation coefficient (CV) of determination results of high concentration WuTac standard by the developed ELISA was less than 15%. Tile developed ELISA showed a accuracy of 99. 05% ± 5. 00%(92. 43% - 110. 02%) and good specificity. The determination results of clinical serum specimens proved that WuTac showed a characteristic of linear pharmacokineties within a concentration range of 0. 05 - 0. 2 mg/kg. Conclusion A double antibody sandwich ELISA for WuTac concentration in serum was developed, with sensitivity, precision and accuracy meeting the requirements of pharmacokinetic study on biologics.
出处 《中国生物制品学杂志》 CAS CSCD 2009年第5期505-507,共3页 Chinese Journal of Biologicals
关键词 抗CD25单克隆抗体 药代动力学 双抗体夹心ELISA Anti-CD25 McAb Pharmacokinetics Double antibody sandwich ELISA
  • 相关文献

参考文献7

  • 1Soulillou JP, Cantarovich D, Le Mauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.!) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N. Engl J Med, 1990, 322(17): 1175-1182.
  • 2Kirkman RL, Shapiro ME, Carpenter CB, et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation, 1991, 51 ( 1 ): 107-113.
  • 3Van Gelder T, Zietse R, Mulder AH, et al. A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation. Transplantation, 1995, 60(3): 248-252.
  • 4Fayer BE, Soui PP, Binger MH, et al. Determination of humanized anti-Tac in human serum by a sandwich enzyme-linked immunosorbent assay. J Immunol Methods 1995, 186( 1 ): 47-54.
  • 5Dowling TC, Chavaillaz PA, Young DG, et al. Phase 1 Safety and pharmacokinetic study of chimeric routine-human monoclonal antibody cαStx2 administered intravenously to healthy adult volunteers. Antimicrob Agents Chemother, 2005, 49(5 ): 1808-1812.
  • 6i Waldmann TA, White JD, Goldman CK, et al. The interleukin-2 receptor: A target for monoclonal antibody treatment of human T- Cell lymphotrophic virus I-induced adult T-Cell leukemia. Blood, 1993, 82(6): 1701-1712.
  • 7Maes BD, Vanrenterghem YF. Anti-interleukin-2 receptor monoclonal antibodies in renal transplantation. Nephrol Dial Transplant, 1999( 14): 2824-2826.

同被引文献23

  • 1徐淑菲,孔繁德,周斌华.牛传染性鼻气管炎PCR检测方法的建立[J].中国动物检疫,2006,23(11):26-28. 被引量:6
  • 2晁学元.应用ELISA检测牛传染性鼻气管炎[J].中国兽医杂志,2007,43(5):63-63. 被引量:3
  • 3Tsurushita N, Hinton PR, Kumar S. Design of humanized antibodies: from anti-tae to Zenapax. Methods, 2005, 36 ( 1 ): 69-83.
  • 4Paseual J, Marcen R, Ortuno J. Anti-interleukin-2 receptor anti-bodies: basiliximab and daelizumab. Nephrol Dial Transplant, 2001, 16 (9): 1756-1760.
  • 5Clark M. Antibody humanization: a case of the "emperors new clothes". Immunol Today, 2000, 21 (8): 397-402.
  • 6Coloma M J, Hastings A, Wims LA, et al. Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J Immunol Methods, 1992, 152 (1): 89-104.
  • 7Norderhaug L, Olafsen T, Michaelsen TE, et al. Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells. J Immunol Methods, 1997, 204 (1): 77-87.
  • 8Li J, Zhang C, Jostock T, et al. Analysis of IgG heavy chain to light chain ratio with mutant Encephalomyocarditis virus internal ribosome entry site. Protein Eng Des Sel, 2007, 20 (10): 491- 496.
  • 9Carton JM, Sauerwald T, Hawley-Nelson P, et ah Codon engineering for improved antibody expression in mammalian cells. Protein Expr Purif, 2007, 55 (2): 279-286.
  • 10Kim CH, Oh Y, Lee TH. Codon optimization for high-level expression of human erythropoietin (EPO) in mammalian cells. Gene, 1997, 199 ( 1-2): 293-301.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部